Quick answer: Precision medicine uses genetic, genomic, metabolomic, and microbiome data to customize prevention and treatment strategies for each individual—rather than applying population-average recommendations. Pharmacogenomics testing (analyzing CYP2D6, CYP2C19, CYP3A4, and other drug-metabolizing enzyme genes) is clinically validated to prevent adverse drug reactions in 30-40% of patients started on standard medication doses, and MTHFR genetic testing identifies the 25-30% of people with impaired folate metabolism who require methylated B vitamins rather than standard folic acid supplementation.
The Precision Medicine Revolution: From Population to Person
The “one size fits all” approach to medical care—where population-average guidelines drive treatment decisions for each individual—is increasingly understood to be both inadequate and potentially harmful. Individual variation in drug metabolism, nutrient requirements, disease risk, treatment response, and optimal lifestyle parameters is driven by the 4-5 million common genetic variants (SNPs) that distinguish any two individuals, the 12-15 trillion microorganisms in the gut microbiome (whose composition is as unique as a fingerprint), the epigenome (the 80%+ of gene expression that is environmentally modifiable), the proteome (the dynamic expression of thousands of proteins whose patterns shift with disease), and the metabolome (the real-time biochemical snapshot of all metabolic processes).
The National Institutes of Health All of Us Research Program (n=1 million+ participants), the UK Biobank (n=500,000), and commercial databases (23andMe, AncestryDNA—now holding genetic data for 20+ million individuals) are generating unprecedented datasets linking genetic variation to health outcomes. The Human Genome Project’s completion (2003) enabled identification of the genetic variants underlying Mendelian diseases; genome-wide association studies (GWAS) have now identified over 100,000 genetic loci associated with common diseases at genome-wide significance—enabling polygenic risk scores (PRS) that integrate thousands of individually small-effect variants into clinically actionable composite risk estimates for cardiovascular disease, type 2 diabetes, breast cancer, inflammatory bowel disease, and dozens of other conditions.
Precision medicine in functional medicine practice integrates three primary layers: (1) Genomics—the constitutional DNA variants that determine individual risk, drug metabolism, nutrient needs, and physiological tendencies; (2) Epigenomics—the methylation, acetylation, and chromatin modifications that control gene expression in response to diet, lifestyle, stress, and environment (modifiable via lifestyle interventions); and (3) Clinical multi-omics (metabolomics, proteomics, microbiomics)—providing the real-time snapshot of how genes are actually being expressed in the patient’s current biological context. The integration of these layers allows a level of personalization unavailable through standard population-medicine approaches.
Pharmacogenomics: The Right Drug at the Right Dose
Pharmacogenomics (PGx)—the study of how genetic variation affects drug response—is the most immediately clinically validated application of precision medicine, with FDA-approved pharmacogenomic guidance for over 200 drugs. The central determinants of drug pharmacokinetics are the cytochrome P450 (CYP) liver enzymes that metabolize approximately 70-80% of all commonly prescribed medications. Genetic variants in CYP enzyme genes create four phenotypic categories: Poor Metabolizers (PM, lacking functional enzyme—drugs accumulate causing toxicity), Intermediate Metabolizers (IM, reduced activity—higher-than-standard exposure), Normal/Extensive Metabolizers (NM/EM, standard activity—as the drug was designed), and Ultrarapid Metabolizers (UM, multiple gene copies—drugs cleared too quickly for efficacy).
CYP2D6 is the most clinically important PGx gene, metabolizing approximately 25% of all prescribed drugs including most antidepressants (SSRIs, TCAs, venlafaxine), opioid analgesics (codeine to morphine conversion), antipsychotics (risperidone, haloperidol), beta-blockers (metoprolol, carvedilol), and tamoxifen (requires CYP2D6 conversion to active endoxifen—poor metabolizers lose tamoxifen’s breast cancer preventive efficacy). CYP2D6 poor metabolizers (5-10% of Caucasians, 1-2% of Asians) cannot convert codeine to morphine—experiencing no analgesia while developing nausea. Conversely, CYP2D6 ultrarapid metabolizers (5-30% of Ethiopian/North African populations) convert codeine to morphine too rapidly—potentially causing respiratory depression, particularly dangerous in nursing infants of ultrarapid metabolizer mothers given postoperative codeine.
CYP2C19 metabolizes clopidogrel (Plavix, requiring conversion to active thienopyridine metabolite), PPIs (omeprazole, pantoprazole), antidepressants (escitalopram, sertraline, amitriptyline), antifungals, and anticonvulsants. CYP2C19 poor metabolizers (3-8% of Caucasians, 15-20% of Asians)—known as “loss of function” (LoF) carriers—cannot activate clopidogrel, the standard dual antiplatelet therapy after coronary stent placement. The FDA added a black box warning in 2010: CYP2C19 LoF carriers on clopidogrel have 3.58-fold higher risk of cardiovascular events. Genetic testing prior to clopidogrel prescription identifies patients who require alternative antiplatelet therapy (ticagrelor, prasugrel—which don’t require CYP2C19 activation). For PPIs, ultrarapid CYP2C19 metabolizers (approximately 20-30% of patients) metabolize PPIs too rapidly—achieving inadequate gastric acid suppression at standard doses, explaining treatment failure that’s often attributed to “refractory GERD” rather than pharmacogenomic variation.
CYP3A4/CYP3A5 comprise the most abundant hepatic CYPs, metabolizing approximately 50% of all drugs including statins (atorvastatin, simvastatin—CYP3A4 inhibition by clarithromycin or grapefruit increases statin blood levels, causing myopathy), immunosuppressants (tacrolimus, cyclosporine—critical narrow therapeutic window drugs), calcium channel blockers, benzodiazepines, and many chemotherapy agents. CYP3A4/5 phenotype classification is less straightforward than CYP2D6 due to multiple variants with complex interactions, but CYP3A5 expressors (approximately 70-80% of African ancestry, 20-30% of Caucasians) have significantly increased tacrolimus clearance—requiring approximately 1.5-2× higher tacrolimus doses to achieve target trough levels in organ transplant recipients.
The clinical impact of pharmacogenomics is substantial: a meta-analysis (Verbelen 2017, Pharmacogenomics) found that PGx-guided prescribing significantly reduced adverse drug reactions (ADRs) and hospitalizations. The PREPARE trial (van der Graaf 2022, Lancet, n=6,944 in 7 European countries) randomized patients to PGx-guided prescribing vs. standard of care for 16 pharmacogenes and 42 drugs—finding a significant 30% reduction in clinically relevant ADRs in the PGx-guided group. Multiple commercial PGx panels (GeneSight, Genomind, Tempus One—testing 8-24 pharmacogenes with clinical actionability reports) are now available, with approximately $250-500 cost (increasingly covered by insurance), providing a one-time lifetime test that informs all future prescribing decisions.
MTHFR and the Methylation Cycle
The MTHFR gene (methylenetetrahydrofolate reductase) encodes the enzyme that converts 5,10-methyleneTHF to 5-methylTHF—the primary form of folate required to donate methyl groups for homocysteine remethylation to methionine, ultimately producing SAM-e (S-adenosylmethionine), the body’s universal methyl donor. SAM-e methyl groups are essential for: DNA methylation (epigenetic gene regulation, tumor suppressor maintenance), neurotransmitter synthesis (norepinephrine, epinephrine, serotonin, dopamine—all require methylation steps), phosphatidylcholine synthesis (neuronal membrane maintenance), creatine synthesis (largest consumer of SAM-e, representing 40% of total methylation capacity), and detoxification conjugation reactions in Phase II liver metabolism.
Two common MTHFR polymorphisms have significant clinical implications: C677T (rs1801133)—the thermolabile variant, found in approximately 10-15% of Caucasians in homozygous TT form (reducing MTHFR enzyme activity by 70%), and approximately 40-50% heterozygous CT (reducing activity by 35%); and A1298C (rs1801131)—found in approximately 7-12% homozygous CC and 35-40% heterozygous AC (reducing activity by 20-40%). Compound heterozygosity (one C677T + one A1298C allele) found in approximately 20-30% of the population reduces activity by 50-65%. The critical clinical implication is that standard folic acid supplementation (the synthetic oxidized form found in prenatal vitamins and fortified foods) requires MTHFR to convert it to the biologically active 5-MTHF—a conversion that MTHFR variant carriers perform inefficiently. 5-methyltetrahydrofolate (5-MTHF, sold as methylfolate, L-5-MTHF, Metafolin, or Deplin) bypasses MTHFR entirely and is immediately bioavailable for the methylation cycle.
The clinical consequences of MTHFR variant-driven methylation impairment include: elevated homocysteine (below-normal methylation → reduced homocysteine remethylation → accumulation; homocysteine above 10 µmol/L is an independent cardiovascular, thrombotic, and neurocognitive risk factor); impaired DNA methylation (potentially increasing cancer risk via tumor suppressor gene promoter hypomethylation); reduced SAM-e (contributing to depression—SAM-e supplementation has meta-analysis-level evidence for antidepressant efficacy, and MTHFR carriers have demonstrably lower SAM-e synthesis capacity); neural tube defect risk in pregnant women (the original clinical validation of MTHFR C677T, driving current folate supplementation in pregnancy—but as 5-MTHF, not folic acid, for variant carriers); poor response to methotrexate (which inhibits DHFR→MTHFR→methylation, more severely impairing already-compromised MTHFR variants); and treatment-resistant depression in patients taking standard SSRI/SNRI doses (Papakostas 2012 trial of 15 mg methylfolate augmentation in MTHFR C677T carriers showed significant SSRI response improvement).
Polygenic Risk Scores: Predicting Disease Before Symptoms
Individual genetic variants rarely confer large disease risk in isolation—instead, the complex common diseases (cardiovascular disease, type 2 diabetes, breast cancer, colorectal cancer) result from the additive effects of hundreds to thousands of variants, each contributing small independent risk increments. Polygenic Risk Scores (PRS) aggregate these small-effect variants across the genome into a composite score that ranks an individual’s genetic predisposition on a continuous scale relative to the population distribution.
The coronary artery disease PRS (developed from GWAS data across hundreds of thousands of individuals) achieves risk stratification comparable to the most powerful single gene mutations: the top 8% of PRS scorers have 4× higher myocardial infarction risk than average—similar to the risk conferred by familial hypercholesterolemia, a single rare Mendelian mutation (Khera 2018, Nature Genetics). Critically, the PSAM study (Natarajan 2021, NEJM) demonstrated that individuals in the top quintile of coronary CAD PRS had significantly larger absolute risk reductions from statin therapy than those in the lowest quintile—establishing PRS as a predictor not just of disease risk but of treatment benefit magnitude.
Breast cancer PRS integrates data from over 300 common variants, achieving risk stratification independent of BRCA1/2 status. Women in the top 1% of breast cancer PRS have lifetime risks comparable to BRCA2 carriers (22-25% vs. general population 12%)—an unrecognized high-risk group outside of rare variant testing. Combined PRS + BRCA1/2 + clinical factors (TYRER-CUZICK model) achieves individual lifetime risk estimates approaching 80% specificity for identifying women who would benefit from enhanced screening (annual MRI + mammography), risk-reducing medications (tamoxifen, raloxifene—each reducing risk approximately 30-40% in high-risk women), or risk-reducing surgery in the highest-risk tier.
Commercial PRS testing (Genomic Life, Invitae, Color Genomics) now offers multi-disease PRS panels alongside rare variant testing (BRCA1/2, Lynch syndrome, PALB2, CHEK2)—enabling a comprehensive genetic risk assessment for the common diseases most likely to affect morbidity and mortality. The clinical actionability of PRS results depends on having specific preventive interventions available—highest utility currently exists for cardiovascular disease (statin therapy, BP management), breast and colorectal cancer (enhanced screening, chemoprevention), type 2 diabetes (intensive lifestyle intervention—DPP trial showed lifestyle produces larger absolute risk reduction in genetically higher-risk individuals), and atrial fibrillation (informing antithrombotic therapy decisions and monitoring intensity).
Nutrigenomics: Precision Nutrition Based on Genetic Variation
Nutrigenomics examines how genetic variants affect individual responses to specific dietary patterns, foods, and nutrients—explaining why the same diet produces dramatically different weight, metabolic, and health outcomes in different individuals. Key validated nutrigenomic variants with clinical utility include:
APOE genotype and dietary fat: As described in functional neurology, APOE4 carriers have significantly different LDL responses to saturated fat and different DHA biosynthesis capacity than APOE3 homozygotes. APOE4 carriers placed on a high-saturated-fat diet show dramatically larger LDL-C increases (average +30 mg/dL vs. +5 mg/dL in APOE3) and higher VLDL remnants—making low saturated fat, high MUFA (Mediterranean) dietary patterns particularly important for APOE4 carriers, while APOE3 homozygotes show less LDL response to saturated fat variation.
FTO and obesity risk: The fat mass and obesity-associated (FTO) gene variant rs9939609 (A allele, found in approximately 45% of Europeans) increases obesity risk by approximately 1.7× per allele via unclear mechanisms (possibly affecting food reward, satiety signaling, and energy expenditure). Critically, the PREDIMED substudy (Shai 2010) found that Mediterranean diet attenuated the FTO obesity risk—individuals with the high-risk AA genotype had obesity prevention equivalent to non-risk-genotype individuals when adhering to Mediterranean diet, suggesting that this genetic risk is largely modifiable by dietary pattern choice.
FADS1/FADS2 and omega-3 conversion: Fatty acid desaturase genes (FADS1/FADS2) encode the Δ5- and Δ6-desaturase enzymes that convert short-chain omega-3 (ALA from plant sources) to long-chain EPA and DHA. The rs174537 FADS1 variant (T allele frequency approximately 30% in Caucasians) dramatically reduces desaturase efficiency—meaning individuals with this variant (a substantial portion of the population) are essentially unable to convert plant-based ALA into the EPA and DHA that produce anti-inflammatory benefits. These individuals require preformed EPA/DHA from marine sources or algae supplements; vegetarian/vegan diets with only ALA supplementation (flaxseed, chia seeds, hemp) are biologically insufficient for this genotypic subgroup.
Lactase persistence (LCT gene): The lactase persistence variant (rs4988235 T allele) evolved in European and some African populations approximately 7,500 years ago with dairy farming—non-carriers (still the global majority: 65% of adults worldwide) have lactase activity declining after childhood, causing lactose malabsorption with symptoms ranging from none (when colonic lactase-expressing bacteria compensate) to significant bloating, cramping, and diarrhea. Genetic testing distinguishes primary lactase non-persistence (LNP, genetic) from secondary lactase deficiency (acquired, due to intestinal damage—celiac, Crohn’s, rotavirus, SIBO) from IBS-associated symptoms misattributed to lactose, enabling precise dietary guidance without unnecessary avoidance or inappropriate attribution of symptoms.
HLA-DQ2/DQ8 and celiac disease/gluten sensitivity: Celiac disease (autoimmune destruction of intestinal villi triggered by gliadin/glutenin proteins in wheat, barley, rye) occurs almost exclusively in carriers of HLA-DQ2 (approximately 30% of Caucasians) or HLA-DQ8 (approximately 8% of Caucasians). The absence of both alleles makes celiac disease effectively impossible (>99.9% negative predictive value)—useful for ruling out celiac in patients in whom biopsy is challenging or whose symptoms are being investigated. The presence of HLA-DQ2/DQ8 does not diagnose celiac (30% of the general population carries these alleles; only 1% develop celiac)—but combined with positive anti-TTG IgA and anti-deamidated gliadin peptide IgG antibodies, provides complete diagnostic confirmation. Non-celiac gluten sensitivity (NCGS)—symptomatic response to gluten without celiac autoimmunity or wheat allergy—affects an estimated 6% of the population and is not HLA-associated, though patients often self-diagnose based on symptom improvement with gluten elimination.
Metabolomics and Real-Time Biochemical Assessment
Metabolomics—the comprehensive measurement of small-molecule metabolites in blood, urine, or tissue—provides a real-time snapshot of the body’s actual biochemical activity, integrating the effects of genetics, epigenetics, gut microbiome, diet, medications, and environmental exposures into a single composite picture. Unlike genomics (which measures potential), metabolomics measures what is actually happening in the biochemistry of each individual patient at the time of testing.
The Organic Acids Test (OAT)—measuring 70+ organic acid metabolites in a first-morning urine specimen—provides the most clinically comprehensive functional metabolomics panel in routine practice. OAT markers assess: mitochondrial function (Krebs cycle organic acids: citrate, isocitrate, aconitate, succinate, fumarate, malate—elevated or suppressed patterns indicate specific enzymatic blockages; fatty acid oxidation markers: ethylmalonate, adipate, suberate—elevated in carnitine deficiency or medium-chain acyl-CoA dehydrogenase dysfunction); B vitamin status (functional, not serum—including methylmalonate for functional B12, xanthurenic acid for B6, FIGlu for folate); neurotransmitter metabolites (HIAA for serotonin turnover, HVA/VMA for dopamine/norepinephrine catabolism—providing indirect assessment of monoamine metabolism without invasive CSF sampling); detoxification capacity (2-methylhippuric acid, pyroglutamate—reflecting glycine and glutathione depletion states); and dysbiosis markers (arabinose for Candida; HPHPA and 4-cresol for Clostridium species overgrowth; tartaric, citramalic for Aspergillus).
Targeted amino acid analysis provides another metabolomic layer: tryptophan is the precursor to serotonin (via tryptophan hydroxylase→5-HTP→5-HT), kynurenine (via IDO/TDO—the inflammatory “tryptophan steal”), and niacin/NAD+ (via kynurenine pathway). The kynurenine:tryptophan ratio measures IDO enzyme activity, which is upregulated by inflammation—a high ratio indicates tryptophan is being diverted away from serotonin toward the quinolinic acid (neurotoxic NMDA agonist) branch of the kynurenine pathway, providing a molecular link between inflammation, depression, and neurotoxicity measurable in a plasma sample. Similarly, measuring the tyrosine→phenylalanine ratio (low ratio indicates inadequate phenylalanine hydroxylase activity, reducing substrate for dopamine/norepinephrine synthesis); SAM-e/SAH ratio (the methylation index—below 4:1 indicates methylation capacity exhaustion); and branched-chain amino acids (BCAA: leucine, isoleucine, valine—elevated in insulin resistance predicting T2DM 5 years before diagnosis in the Bhupathiraju 2011 data).
Frequently Asked Questions
Should everyone get pharmacogenomics testing, or is it only for certain patients?
Pharmacogenomics testing is most cost-effective when ordered before starting medications that are known to have high inter-individual variability due to CYP enzyme polymorphisms—particularly antidepressants, antipsychotics, opioid pain medications, anticoagulants, anti-platelet agents (clopidogrel), and tamoxifen. Since PGx results apply throughout a patient’s lifetime (genes don’t change), the test is especially valuable for younger patients starting long-term psychiatric or cardiovascular medications. The PREPARE trial established a 30% reduction in serious adverse drug reactions with PGx-guided prescribing—with obvious quality-of-life and healthcare cost implications. Cost has decreased substantially ($250-500 for comprehensive panels), with many insurance plans now covering PGx testing following FDA guidance updates. Even for patients not currently on high-risk medications, a one-time comprehensive PGx panel provides information relevant to future prescribing decisions.
I tested positive for MTHFR variants—what should I do?
MTHFR variants are very common (25-40% of the population have at least one C677T or A1298C allele) and most carriers live normally without intervention. Clinical management priorities: (1) Replace standard folic acid in all supplements with active L-5-methylfolate (L-5-MTHF, 400-800 µg/day for general health, up to 15 mg/day for treatment-resistant depression under physician guidance); (2) Check fasting homocysteine—if above 10 µmol/L, add methylcobalamin (active B12, 1,000-2,000 µg/day) and pyridoxal-5-phosphate (P5P, active B6, 25-50 mg/day) alongside 5-MTHF; (3) Consider SAM-e supplementation (400-800 mg/day) if depression, low energy, or elevated homocysteine is present; (4) Avoid high-dose folic acid (above 1 mg/day of synthetic folic acid)—unmetabolized folic acid may accumulate in MTHFR variant carriers, potentially masking B12 deficiency and having other adverse effects. Prenatal: MTHFR-variant pregnant women should use methylfolate-containing prenatal vitamins from 3 months before conception.
What is a polygenic risk score and how is it different from BRCA testing?
BRCA1/2 testing looks for rare, high-impact mutations in two specific genes—these mutations are present in approximately 1 in 400 people but confer 60-80% lifetime breast cancer risk. Polygenic risk scores (PRS) integrate hundreds to thousands of common genetic variants, each conferring very small individual risk increments—but collectively producing a continuous gradient of disease risk across the entire population. The top 1% of breast cancer PRS scorers have lifetime risk comparable to BRCA2 carriers, despite having none of the rare high-impact variants. PRS and BRCA testing are complementary: optimal risk assessment combines both—PRS identifies the common polygenic high-risk tier while BRCA identifies the rare monogenic high-risk tier. Together with clinical factors, they enable precision risk stratification informing individualized screening intervals, chemoprevention thresholds, and surgical consultation decisions.
What is the Organic Acids Test and who should consider it?
The Organic Acids Test (OAT) is a first-morning urine test measuring 70+ metabolic markers that collectively assess mitochondrial function, B vitamin status, neurotransmitter metabolism, detoxification capacity, and gut dysbiosis markers. It is particularly valuable for patients with: unexplained fatigue, fibromyalgia, or chronic pain (assessing mitochondrial dysfunction and Krebs cycle abnormalities); treatment-resistant depression or anxiety (measuring neurotransmitter catabolism and tryptophan-kynurenine ratios); recurrent yeast infections or suspected SIBO/dysbiosis (Candida arabinose, Clostridium HPHPA markers); nutritional optimization (functional B vitamin adequacy independent of serum levels—serum B12 can be normal while functional B12 deficiency exists due to methylation pathway issues); and chemical sensitivity or suspected toxic burden (detoxification pathway capacity markers). The OAT is not a diagnostic test for specific diseases but a functional assessment of biochemical individuality—guiding targeted supplementation and lifestyle modification in complex chronic illness.
Precision medicine transforms functional medicine from educated guesswork to biologically confirmed personalization—replacing the question “what should a person like me do?” with “what does my specific genetic, metabolomic, and microbiome profile indicate I should do?” As genomic sequencing becomes increasingly affordable (whole genome sequencing at $200-400 is approaching clinical routine), and as longitudinal multi-omic datasets create increasingly accurate disease prediction models, the precision medicine approach will become the foundation of preventive healthcare rather than a specialty service. At The Private Practice, Dr. Biernacki integrates comprehensive genetic testing (pharmacogenomics, MTHFR/methylation, APOE, polygenic risk scores), functional metabolomics (OAT, amino acids, advanced lipid panel), and microbiome assessment into a personalized precision health protocol tailored to each patient’s unique biological fingerprint. To schedule precision medicine consultation, call (810) 206-1402.